OncRef

Clinical Trial: NCT05751798

Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

Status:

RECRUITING

Phase:

Phase 1

Lead Sponsor:OSE Immunotherapeutics
Information Provided By:OSE Immunotherapeutics
Last Update Posted:2026-06-04

Study Overview

Brief Summary

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Official Title

A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas

Conditions

Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)

Intervention / Treatment

  • Drug: Part A: OSE-279 100mg
  • Drug: Part A: OSE-279 300mg
  • Drug: Part A: OSE-279 600mg
  • Drug: Part B: OSE-279 600 mg and OSE2101
  • Drug: Part C: OSE-279 600 mg and OSE2101 - HLA-A2 positive
  • Drug: Part C: OSE-279 600 mg - HLA-A2 positif
  • Drug: Part C: OSE-279 600 mg - HLA-A2 negative

Other Study ID Numbers

  • OSE-279-C101
  • 2022-001136-28

Start Date (Actual)

2022-12-20

Primary Completion Date (Estimated)

2029-12

Study Completion Date (Estimated)

2029-12

Enrollment (Estimated)

41

Study Type

Interventional

Phase

Phase 1, Phase 2